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SUMMARY
Background
In HCV-infected cirrhotic patients with successfully treated early hepatocel-
lular carcinoma (HCC), the time to HCC recurrence and the effects of sus-
tained viral eradication (SVR) by interferon (IFN)-based or IFN-free
regimens on HCC recurrence remain unclear.
Aim
To perform an indirect comparison of time to recurrence (TTR) in patients
with successfully treated early HCC and active HCV infection with those of
patients with SVR by IFN-based and by IFN-free regimens.
Methods
We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic
Liver Cancer Stage A/0 HCC who had a complete radiological response
after curative resection or ablation. Active HCV infection was present in
328, selected from the Italian Liver Cancer group cohort; 58 patients had
SVR achieved by IFN-free regimens after HCC cure, and 57 patients had
SVR achieved by IFN-based regimens after HCC cure. Individual data of
patients in the last two groups were extracted from available publications.
Results
TTR by Kaplan–Meier curve was signiﬁcantly lower in patients with active
HCV infection compared with those with SVR both by IFN-free (P = 0.02)
and by IFN-based (P < 0.001) treatments. TTR was similar in patients with
SVR by IFN-free or by IFN-based (P = 0.49) strategies.
Conclusion
In HCV-infected, successfully treated patients with early HCC, SVR
obtained by IFN-based or IFN-free regimens signiﬁcantly reduce tumour
recurrence without differences related to the anti-viral strategy used.
Aliment Pharmacol Ther
ª 2016 John Wiley & Sons Ltd 1
doi:10.1111/apt.13821
Alimentary Pharmacology and Therapeutics
INTRODUCTION
Hepatocellular carcinoma (HCC) is the third-leading
cause of cancer-related death in men globally, and the
leading cause of mortality in patients with cirrhosis.1, 2
Cirrhosis is the strongest risk factor for HCC, with hep-
atitis C virus (HCV) being a major risk factor in the
Western world as well as in Japan.3 Orthotopic liver
transplantation (OLT) is the deﬁnitive treatment for
removal of an HCC and cirrhotic liver, but it cannot be
offered to all patients due to limitations, such as graft
availability and rigorous selection criteria.4–6
When diagnosed in an early disease stage [(Barcelona
Clinic Liver Cancer stage 0 or A (BCLC 0/A)], surgical
resection and loco-regional ablation are potentially cura-
tive treatments, with 5-year survival rates of 60–80% and
40–70%, respectively.4–6 Unfortunately, tumour recur-
rence contributes to long-term mortality after tentatively
curative treatment of early HCC.4–8 Although HCC
tumour recurrence remains high overall (50% at 3 years
and 70% at 5 years), the available evidence is highly
heterogeneous and data are not available speciﬁcally for
HCV-infected patients.
Currently, because of the burden of HCC recurrence
and the lack of strategies with proven prevention efﬁ-
cacy, there is a serious unmet clinical need in the area of
adjuvant therapy for patients treated for early HCC with
persistent HCV infection.9 In fact, the STORM ran-
domised controlled trial of sorafenib as an adjuvant
treatment after potentially curative therapy for HCC
failed to show a signiﬁcant treatment effect regarding
HCC recurrence in either HCV-infected or uninfected
patients.10 Classical 11 and competing risk multistage 12
models have demonstrated clearly that sustained virolog-
ical response (SVR) by interferon (IFN)-based therapies
reduces the de novo occurrence of HCC in HCV-related
cirrhosis with or without clinical portal hypertension.
However, available data on the impact of SVR by IFN-
based vs. newer IFN-free regimens on HCC recurrence
are inconsistent. Speciﬁcally, when considering IFN-
based regimens, ﬁve meta-analyses13–17 of aggregate data
of small randomised controlled trials in heterogeneous
populations of patients with tentatively cured HCV-
related early HCC showed conﬂicting results regarding
the beneﬁt of SVR on HCC recurrence. Moreover, some
of these studies combined all IFN-treated patients with
and without SVR, and the non-availability of individual
data precluded the analysis of recurrence as a time-
dependent variable. Otherwise, data for IFN-free regi-
mens using direct antiviral agents (DAAs) indicate high
rates of early HCC recurrence in small cohorts of HCV-
related cured HCC patients, raising concerns about the
as yet unproven beneﬁt of adjuvant DAA-based ther-
apy.18, 19
We aimed to estimate time to HCC recurrence in suc-
cessfully treated early HCC patients with active HCV
infection using the Italian Liver Cancer (ITA.LI.CA.)
group cohort, and to compare the observed recurrence
rate with that of patients with SVR achieved by IFN-
based or IFN-free regimens, using pooled estimated indi-
vidual data from the literature.
MATERIALS AND METHODS
Patients
Patients with successfully treated, HCV-related early
HCC with active HCV infection. Currently, the ITA.-
LI.CA. database contains data from 6595 patients with
HCC diagnosed consecutively from 1987 to 2015 at 24
Italian medical institutions. Since 2007, the ITA.LI.CA.
database has included follow-up clinical and imaging
data that were collected prospectively and updated every
2 years. After data collection and before statistical evalu-
ation, the group coordinator (F.T.) examined the consis-
tency of the datasets. If clariﬁcations or additional
information were needed, the data were resubmitted to
the relevant centre. The presence of cirrhosis was deter-
mined according to histological ﬁndings or clinical
evidence, and liver function was evaluated based on
Child–Pugh20 and MELD scores.21 The presence of oeso-
phageal varices was assessed by upper digestive endoscopy
and was classiﬁed as absent, small, medium or large.22
The diagnosis of HCC was made by ultrasound-
guided biopsy or by non-invasive criteria according to
the guidelines published at the time of patient inclusion.
Performance status (PS) was scored according to the
Eastern Cooperative Oncology Group (ECOG) system.23
HCC staging was assessed according to both the Milan
criteria24 and BCLC classiﬁcation, and treatments were
performed according to the BCLC schedule4, 5 unless
individual centre care providers chose different patient-
tailored therapeutic options. Patients with early tumours
(BCLC A) were considered for resection, OLT or local
ablation. Transarterial chemoembolisation was performed
in patients with intermediate-stage (BCLC B) tumours.
Starting in July of 2008, compensated patients with
advanced HCC (BCLC C) and patients with intermedi-
ate-stage HCC who were not eligible for or failed loco-
ablative therapies were treated with sorafenib.
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For this retrospective study of prospectively collected
data, we included all early HCC patients with HCV-
related compensated cirrhosis who achieved complete
radiological response after tentatively curative treatment,
either resection or ablation. The patient selection process
is illustrated in Figure 1. Complete radiological response
was determined by applying validated imaging criteria to
multiphasic, contrast-enhanced computed tomography
(CT) or magnetic resonance imaging (MRI) of the abdo-
men approximately 1 month after either tumour resec-
tion or the last loco-regional treatment (thermal
ablation). Blood cell counts, serum chemistry and serum
a-fetoprotein (AFP) levels were measured by standard
laboratory procedures. HCV markers were detected with
commercial kits.
The study endpoint was time to recurrence (TTR),
deﬁned as the time from HCC treatment with curative
intent to the ﬁrst disease recurrence documented by
radiological assessment. For this purpose, after tentatively
curative treatment for HCC with a documented complete
radiological response, all patients were followed in speci-
ﬁc out-patient clinics. The follow-up protocol included
clinical assessment by physical examination, ultrasound
scans, and biochemistry every 3 months, as well as mul-
tiphasic CT or MRI every 6 months. HCC recurrence
was diagnosed on the basis of combined abnormal ﬁnd-
ings on ultrasonography and on one additional dynamic
imaging technique conﬁrming hypervascularisation in
the arterial phase with washout in the portal venous or
late venous phase. All participating ITA.LI.CA centres
had high-quality and updated radiological facilities.
Recurrences were treated whenever possible according to
treatment plans devised at each centre.
Patients with successfully treated, HCV-related early
HCC with SVR following IFN-based therapy. We
conducted a systematic review and meta-analysis of
studies evaluating the efﬁcacy of IFN to prevent HCC
recurrence after tentatively curative treatment in HCV-
related cirrhosis. We included only studies reporting
HCC recurrence curves in patients with SVR, to obtain
a pooled actuarial HCC recurrence curve in patients
with successfully treated, HCV-related early HCC with
SVR following IFN-based therapy. After a review of
the literature, three studies25–27 fulﬁlled the inclusion
criteria.
Patients with successfully treated, HCV-related early
HCC with SVR following DAA-based therapy. Data were
obtained from a study by Reig and colleagues.18 Speciﬁ-
cally, we extracted the individual data from Figure 2 of
the article, calculated the Kaplan–Meier probability esti-
mates of HCC recurrence, and plotted a Kaplan–Meier
curve.28 We used the time of HCC treatment as the ori-
gin of the Kaplan–Meier curve,.
Statistical analyses
Experienced medical personnel collected data. Continu-
ous variables were expressed as a median and range,
whereas categorical data were reported as counts and
percentages. Individual patient data on TTR were
reported graphically in each of the involved studies and
were extracted by means of speciﬁcally designed digitiz-
ing software.29 The Kaplan–Meier method was used to
estimate TTR probabilities. Statistical signiﬁcance of dif-
ferences in TTR was assessed by means of the log-rank
test.
Potential predictors of TTR were evaluated in the
HCV-infected cohort by ﬁtting a Cox regression model.
All baseline variables in Table 1 were evaluated by uni-
variate analyses. Variables with P ≤ 0.10 in the univari-
ate analyses were included in the ﬁnal multivariate
HCC patients in I.TA.LI.CA. database from 2007
-1456 HCC patients with aetiology other than HCV
HCV-related HCC
Inclusion criteria:
-503 untreatable HCC patients
328 HCV-related early HCC with complete radiological response
after resection or ablation
-797 treated no-early HCC patients
-182 treated early HCC patients without complete
radiological response after resection or ablation
-HCV-related early HCC
-Complete radiological
response after resection or
ablation
N = 3309
N = 1810
Figure 1 | Flow diagram of
patient selection. ITA.LI.CA.,
Italian Liver Cancer; HCC,
hepatocellular carcinoma;
HCV, hepatitis C virus; SVR,
sustained virological response.
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Figure 2 | Time to HCC recurrence in 443 patients with curative resection or ablation of HCC in HCV-related
cirrhosis according to HCV infection status: 323 patients with active HCV infection (group 1), 58 patients with SVR by
IFN-free regimens (group 2), and 57 patients with SVR by IFN-based regimens (group 3). Overall Log-rank P < 0.001.
Log-rank group 1 vs. group 2 P = 0.02. Log-rank group 1 vs. group 3 P < 0.001. Log-rank group 2 vs. group 3
P = 0.49.
Table 1 | Baseline characteristics of 443 patients with complete response after HCC treatment, stratiﬁed according to
HCV infection status
Groups
Active HCV infection
(N = 328)
SVR by IFN-free
therapies (N = 58)
SVR by IFN-based
therapies* (N = 57)
Age, median [range] (years) 72.1 [40–85] 66.3 [45–83] 62.0 [43–80]
Male sex, n (%) 217 (66) 40 (69) 41 (72)
Resection, n (%) 88 (27) 20 (34) 25 (44)
BCLC, n (%)
0 99 (30) 16 (28)
A 229 (70) 42 (72) 57 (100)†
Child–Pugh, n (%)
A 307 (94) 50 (91) 46 (90)
B 21 (6) 3 (5) 5 (10)
C 0 2 (4) 0
Performance status
0 328 (100) 58 (100) 57 (100)
Albumin, median [range] (g/dL) 3.7 [2.3–5.1] 4.0 [2.0–5.0] Not reported
Bilirubin, median [range] (mg/dL) 0.9 [0.3–2.9] 1.0 [0.3–6.0] Not reported
Creatinine, median [range] (mg/dL) 0.8 [0.4–7.7] 0.8 [0.4–2.4] Not reported
Platelets, median [range] (9109/L) 121 [24–332] 101 [33–229] Not reported
PT, median [range] % 81.0 [37–117] 77.5 [12.6–100] Not reported
AFP, median [range] (ng/mL) 22.94 [1–950] 11.45 [1–369] 24 [1–13 846]
* Patient characteristics for the SVR by Interferon group were deduced from those related to the entire IFN arm.
† Number of BCLC 0 patients not available.
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model. To prevent variable co-linearity effects, MELD,
BCLC and Child–Pugh scores were not included in the
same multivariate model.
For all analyses, P < 0.05 were considered statistically
signiﬁcant. All p values were two-tailed, and all conﬁ-
dence intervals (CIs) were 95%. The R Statistical Com-
puting Environment (R Foundation for Statistical
Computing, Vienna, Austria) was used to perform analy-
ses and plot results.
Ethics
Management of the ITA.LI.CA database conforms to all
Italian laws on privacy, and this study met the ethical
guidelines of the Helsinki Declaration. The Institutional
Review Boards of the participating centres approved this
study.
RESULTS
Baseline features of studied populations
The baseline features of patients with successfully treated
HCC and cirrhosis with active HCV infection (hereafter
group 1), with SVR achieved by IFN-free (hereafter
group 2) and with SVR achieved by IFN-based (hereafter
group 3) regimens are summarised in Table 1.
The indirect comparison revealed that the prevalence
of male sex was similar among the three groups, ranging
from 66% in group 1 to 72% in group 3. Median age
decreased progressively from viraemic patients (72 years)
to those achieving SVR by IFN-free treatment (66 years),
and further to those achieving SVR by IFN-based
(62 years) therapies. More than 90% of patients in all
three groups had compensated Child A cirrhosis, with
similar values of baseline liver function and kidney
indexes, such as albumin, bilirubin and creatinine (data
not available for group 3).
All patients had BCLC A HCC and therefore a perfor-
mance status of 0. The proportion of patients who
underwent HCC resection increased progressively from
those with active HCV infection (27%), to those achiev-
ing a SVR following IFN-free regimens (34%), and fur-
ther to those achieving SVR following IFN-based
therapies (44%). Median serum a-FP levels were similar
among groups.
Follow-up
The median length of follow-up after tentatively curative
HCC treatment was similar in patients with active HCV
infection (17 months, range 1–95 months) and those
with SVR following IFN-free regimens (18 months,
range 3–90 months), but was higher in those achieving
SVR following IFN-based therapies (34 months, range
0–138 months).
Recurrences
During follow-up, HCC recurrence developed in 142/328
(43.3%) patients with active HCV infection, in 16/58
(27.6%) patients achieving SVR following IFN-free regi-
mens, and in 22/57 (38.6%) patients achieving SVR fol-
lowing IFN-based therapies (Table 2). The 6-month
recurrence rates were 9.5%, 5.2% and 3.7%, and the
2-year recurrence rates were 40.6%, 26.3% and 15.2% in
patients with active HCV infection, with SVR achieved
following IFN-free treatment, and with SVR achieved
following IFN-based therapies, respectively. Consistent
with these data, TTR by Kaplan–Meier curves was
Table 2 | Follow-up of 443 patients with complete response after HCC treatment, stratiﬁed according to HCV
infection status
Groups
Active HCV infection
(N = 328)
SVR by IFN-free
therapies (N = 58)
SVR by IFN-based
Therapies* (N = 57)
Recurrence during follow-up, n (%) 142 (43.3) 16 (27.6) 22 (38.6)
Follow-up length, median (range) 17 (1–95) 18 (3–90) 34 (0–138)
Recurence rates
6-month 9.5% 5.2% 3.7%
1-year 21.0% 12.9% 5.6%
2-year 40.6% 26.3% 15.2%
3-year 54.5% 33.5% 29.3%
4-year 60.7% 39.1% 41.1%
5-year 64.5% 39.1% 41.1%
Median time to recurrence, mo. (95% CI) 31 (26–38) 72.0 (40.8–N.A.) 82.3 (39.8–N.A.)
Aliment Pharmacol Ther 5
ª 2016 John Wiley & Sons Ltd
SVR in HCV-related HCC patients who had curative treatment
signiﬁcantly shorter in patients with active HCV infec-
tion compared with those with SVR achieved following
either IFN-free (P = 0.02) or IFN-based (P < 0.001)
treatments. TTR was similar in patients with SVR
achieved following IFN-free or IFN-based (P = 0.49)
strategies (Figure 2). Consistent with these data, recur-
rence rates at 6 months, 1 year, 2 years and 3 years did
not differ signiﬁcantly between these two groups
(P = 0.66, P = 0.19, P = 0.34 and P = 0.95 respectively).
Notably, among patients with active HCV infection,
Kaplan–Meier TTR was similar between those who had
previously undergone IFN-based treatment (n = 101)
and those na€ıve to anti-viral therapy (n = 127)
(P = 0.57) (Figure S1). Finally, owing to the availability
of individual data in the viraemic patient group, we were
able to determine by multivariate analysis that bilirubin
(HR = 1.43; 95% CI = 1.02–2.00; P = 0.03), creatinine
(HR = 1.42; 95% CI = 1.11–1.83; P = 0.006) and a-FP
(HR = 1.001; 95% CI = 1.000–1.003; P = 0.04) were the
only independent predictors of HCC recurrence exam-
ined (Table S1).
DISCUSSION
In the present study, we found 6-month and 2-year
HCC recurrence rates of 9.5% and 40.6% in a large
cohort of patients with HCV-related early HCC who
achieved a complete radiological response after tenta-
tively curative resection or ablation. Furthermore, we
demonstrated that SVR by IFN-based or IFN-free regi-
mens reduced the HCC recurrence rate signiﬁcantly
without differences related to the therapeutic strategy.
We also identiﬁed baseline AFP, bilirubin and creatinine
levels as independent predictors of HCC recurrence,
indicating that factors related to tumour aggressiveness
(i.e. AFP),30 advanced liver disease (i.e. bilirubin) and
liver disease prognosis (i.e. bilirubin and creatinine)
increase tumour recurrence risk.
Hepatocellular carcinoma recurs frequently in patients
infected with HCV, and adjuvant therapies with drugs
like sorafenib that directly treat HCC lack efﬁcacy.10
These facts highlight the unmet clinical need for adju-
vant therapy for patients treated for early HCC but with
persistent HCV infection. In this clinical setting, viral
eradication could act as an adjuvant strategy, leading to
reduced HCC recurrence, similar to its impact for HCC
de novo occurrence.11, 12 However, data on the impact of
IFN-based or IFN-free regimens on HCC recurrence are
inconclusive and/or conﬂicting.13–17
To address this relevant concern, we assessed the
effect of SVR on HCC recurrence by comparing TTR in
patients with HCV viraemia with that observed in
patients achieving SVR by IFN-based or IFN-free anti-
viral therapies. Data for patients with active HCV infec-
tion were those previously reported from the ITA.LI.CA
cohort. Data for patients in SVR achieved by IFN-based
therapies were obtained by pooling individual data of
studies estimating the effect of IFN-based SVR on HCC
recurrence in HCV patients. Data for patients in SVR by
IFN-free therapies were obtained by individual data
extracted from the study of Reig and colleagues.18 Nota-
bly, when comparing the three curves, we clearly demon-
strated that SVR, whether achieved via IFN-based or
IFN-free regimens, signiﬁcantly reduces HCC recurrence
rate, with no difference between the two therapeutic
strategies. We observed lower 1-year and 2-year recur-
rence rates, even if not statistically different, in patients
treated with IFN compared with those who received
IFN-free therapies. This trend could be related to the fact
that the former group may be enriched with patients
without early HCC recurrence because early HCC recur-
rence during IFN-based therapy led to therapy drop out
and no SVR.
Consistent with all the above-quoted data, the present
study suggests that the positive impact of anti-viral ther-
apy on HCC recurrence is only the effect of virological
eradication, regardless of the regimen. It is worth noting
that the published experimental data also support the
idea that IFN per se has anti-ﬁbrotic, anti-proliferative,
anti-angiogenic and anti-tumoural effects,31, 32 suggesting
its potential beneﬁt on HCC recurrence also in the
absence of SVR. Despite these interesting speculations,
when evaluating patients with active HCV infection sep-
arately according to previous exposure to IFN, no differ-
ences in HCC recurrence rates were observed. Consistent
with these data, while half of patients in the DAA
group17 had been treated with IFN, no additional beneﬁt
in terms of HCC recurrence reduction was observed in
patients achieving SVR by DAA compared with those
achieving SVR by IFN.
From a clinical point of view, our study (i) demon-
strated that all HCV-infected patients with successfully
treated early HCC should undergo virological eradication
to reduce the probability of HCC recurrence; (ii) pro-
vided evidence about the clinical utility of IFN-free anti-
viral regimens in this clinical setting, where DAAs have
been until now used without any proof of their effective-
ness. Consistent with these data, IFN-free therapies
should be preferred to IFN-based regimens due to their
safety proﬁle and high virological effectiveness, as well as
the possibility to safely treat sicker patients; (iii) ﬁnally
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provided a benchmark for the HCC recurrence rate in
HCV-infected patients to be used as comparator for new
adjuvant strategies.
This study has some limitations. The main limitation
lies in the comparison of groups arising from different
populations and the potentially variant severity of under-
lying liver disease. In addition, recurrence rates in the
retrospective ITA.LI.CA. cohort could be affected by sev-
eral confounding factors, such as alcohol intake, meta-
bolic comorbidities and HCV genotype. However, we are
conﬁdent about the strength of our results because we
used individual data for each group, and because all
patients had early HCC treated by resection or ablation.
Overall, the strict patient selection criteria resulted in a
generally homogeneous population. Finally, the generalis-
ability of these results to different populations and set-
tings is not known. As our study included only patients
with successfully treated early HCC, we did not deter-
mine whether the impact of SVR on HCC recurrence is
the same in patients with more advanced HCC at base-
line.
In conclusion, our results demonstrated that in
patients with successfully treated, HCV-related early
HCC, SVR obtained by IFN-based or IFN-free regimens
reduces tumour recurrence signiﬁcantly without differ-
ences related to the anti-viral strategy used. These data
support the current use of IFN-free regimens in this
particular clinical setting and provide proof of their clini-
cal effectiveness in terms of reducing HCC recurrence.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Time to HCC recurrence in 323 cirrhotic
patients with curative resection or ablation of HCC and
with active HCV according to previous exposure to IFN-
based therapies. Log-rank P = 0.57.
Table S1. Independent predictors of time to recur-
rence in the HCV-infected cohort by ﬁtting a Cox
regression model.
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